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Alzheimer’s disease drug development pipeline: 2019
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aDepartment of Brain Health, University of Nevada, Las Vegas (UNLV), School of Integrated Health Sciences, Las Vegas, NV, USA
bCleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
cCNS Innovations, Henderson, NV, USA
Abstract Introduction: Alzheimer’s disease (AD) has few available treatments, and there is a high rate of fail-
ure in AD drug development programs. Study of the AD drug development pipeline can provide
insight into the evolution of drug development and how best to optimize development practices.
Methods: We reviewed clinicaltrials.gov and identified all pharmacologic AD trials of all agents
currently being developed for treatment of AD.
Results: There are 132 agents in clinical trials for the treatment of AD. Twenty-eight agents are in 42
phase 3 trials; 74 agents are in 83 phase 2 trials; and 30 agents are in 31 phase 1 trials. There is an
increase in the number of agents in each phase compared with that in the 2018 pipeline. Nineteen
agents in trials target cognitive enhancement, and 14 are intended to treat neuropsychiatric and behav-
ioral symptoms. There are 96 agents in disease modification trials; of these, 38 (40%) have amyloid as
the primary target or as one of several effects. Eighteen of the antiamyloid agents are small molecules,
and 20 are monoclonal antibodies or biological therapies. Seven small molecules and ten biologics
have tau as a primary or combination target (18%). Amyloid is the most common specific target in
phase 3 and phase 2 diseasemodification trials. Novel biomarkers (e.g., neurofilament light), new out-
comes (e.g., AD Composite Score [ADCOMS]), enrollment of earlier populations, and innovative
trial designs (e.g., Bayesian adaptive designs) are new features in recent clinical trials.
Discussion: Drug development continues robustly at all phases despite setbacks in several programs
in the recent past. Continuing unmet needs require a commitment to growing and accelerating the
pipeline.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Alzheimer’s disease; Drug development; Clinical trials; Biomarkers; Bayesian design; Adaptive design; Repur-
posed drugs
1. Introduction
Drug discovery and development for Alzheimer’s disease
(AD) is arduous. There have been no new drugs approved
since 2003, and there are no approved disease-modifying
treatments (DMTs) for AD. The challenges of drug develop-
ment have become more complex as potential trial popula-
tions have expanded to include preclinical and prodromal
AD, as well as AD dementia [1–3]. The US Food and
Drug Administration (FDA) has provided guidance for
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clinical trials in AD dementia and predementia AD
including use of a single primary outcome in trials of
prodromal AD, the role of biomarkers in staging
preclinical and prodromal AD, and the use of Bayesian
statistics and adaptive clinical trial designs [4–6]. A new
research framework for the diagnosis of AD based on
amyloid, tau, and neurodegeneration (ATN) biomarkers
was introduced by the National Institute on Aging (NIA)
and the Alzheimer’s Association [7]. This framework allows
more precise classification of stages of AD, especially pre-
dementia stages, and may facilitate clinical trials of DMTs
in AD [8]. Progress in biomarkers relevant to clinical trials
of AD include increased understanding of the role of tau
positron emission tomography (PET) in characterizing and
staging AD and development of new fluid biomarkers such
as neurofilament light and neurogranin that are increasingly
integrated into clinical trials [9,10]. These advances
comprise the foundations for progress in drug development
and demonstrate collaboration among key stakeholders
including basic and translational neuroscientists, clinician-
scientists, pharmacy benefit managers, regulators, the
National Institutes of Health (NIH), advocacy groups, and
participants and family members.
In our annual update on the state of the AD drug develop-
ment pipeline, we build on prior contributions to discuss the
current phase 1, phase 2, and phase 3 clinical trials in AD
[11–13]. We describe clinical trials and experimental
treatments for disease modification, cognitive
enhancement, and neuropsychiatric symptoms of AD. We
note changes from 2018 and discuss specific areas of
interest including repurposed agents, immunotherapies,
novel mechanisms, the use of biomarkers in drug
development, and new trends in AD clinical trials. Our
goal is to continuously learn from the drug development
process, identify best practices, and provide an update and
overview of the current state.
2. Methods
Clinicaltrials.gov provides the source of information for
this review. There are other clinical trial registries, and our
review does not represent an exhaustive listing of every clin-
ical trial in AD. However, the “Common Rule” governing
clinicaltrials.gov mandates registration of all trials from
sponsors with an investigational new drug or investigational
new device [14,15] being assessed in the US. Compliance
with the required trial registration is high [16–18]. The US
has more clinical trials than any other nation, and thus
clinicaltrials.gov includes most agents currently in clinical
trials for AD.
We assayed clinicaltrials.gov as of February 12, 2019,
and the tables and discussion provided apply to the informa-
tion available at that time. We comment on terminated trials
if the information has become publicly available but is not
yet reflected on clinicaltrials.gov. We include all trials of
all agents in phase 1, 2, and 3; if trials are presented as 1/2
or 2/3 in the clinicaltrials.gov database, we use that nomen-
clature in the review. Our trial database tracks trial title; trial
number in clinicaltrials.gov; beginning date; projected end
date; calculated trial duration; duration of treatment expo-
sure; number of subjects planned for enrollment; number
of arms of the study (usually a placebo arm and one or
more treatment arms with different doses); whether a
biomarker was described; subject characteristics; and spon-
sorship (a biopharmaceutical company, NIH, academic med-
ical center, “other” entity such as a consortium or a
philanthropic organization or a combination of these spon-
sors). We used the clinicaltrials.gov labeling and included
trials that were recruiting, active but not recruiting (e.g., tri-
als that have completed recruiting and are continuing with
the exposure portion of the trial), enrolling by invitation,
and not yet recruiting. We did not include trials listed as
completed, terminated, suspended, unknown, or withdrawn.
Information on these trials and reasons for their current sta-
tus may not be publicly revealed. We do not include trials of
nonpharmacologic therapeutic approaches such as cognitive
therapies and caregiver interventions; we do not include
studies of supplements and medical foods. We provide a ta-
ble and brief discussion of new device trials (not included in
Fig. 1). We do not include trials of biomarkers, although we
note whether biomarkers were used in the trials reviewed.
We include stem cell therapies among the interventions re-
viewed (not integrated into Fig. 1).
Drug targets and mechanisms of action (MOA) are
important aspects of this review. MOA was determined
from the information on clinicaltrials.gov or from a compre-
hensive search of the literature. In a few cases, the mecha-
nism is undisclosed and could not be identified in the
literature; we note these agents as having an “unknown” or
“undisclosed” MOA. We grouped the mechanisms into
symptomatic agents or DMTs. We divided the symptomatic
agents into those that are putative cognitive enhancing
agents or those that address neuropsychiatric and behavioral
symptoms. DMTs were divided into small molecules or bi-
ologics including immunotherapies. DMTs were further
divided into those targeting amyloid-related mechanisms,
those that have tau-related MOAs, and those with “other”
mechanisms such as neuroprotection, anti-inflammatory ef-
fects, growth factor promotion, or metabolic effects. The
distinction between symptomatic and disease-modifying
agents can be arbitrary, and some agents may have both
properties. For purposes of this review, we chose what ap-
pears to be the principal MOA.
3. Results
3.1. Overview
As of February 12, 2019, there were 132 agents in 156
trials of anti-AD therapies. Fig. 1 shows the universe of
pharmacologic compounds currently in clinical trials for
AD. Nineteen (14%) agents in trials target cognitive
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enhancement, and 14 (11%) are intended to treat neuropsy-
chiatric and behavioral symptoms. There are 96 (73%)
agents that intend to achieve disease modification; 38
(40%) of these have amyloid; and 17 (18%) have tau as
the primary target or as one of several effects seen in
nonclinical studies. Eighteen of the antiamyloid agents are
small molecules, and 20 are monoclonal antibodies or bio-
logical therapies. Anti-tau agents include seven small mole-
cules and ten biologics.
All compounds in AD clinical trials as of February 12,
2019 (the inner ring shows phase 3 agents; the middle ring
is comprised of phase 2 agents; the outer ring presents phase
1 compounds; agents in green areas are biologics; agents in
purple areas are disease-modifying small molecules; agents
in orange areas are symptomatic agents addressing cognitive
enhancement or behavioral and neuropsychiatric symptoms;
the shape of the icon shows the population of the trial; the
icon color shows the class of target for the agent.). Bolded
names represent agents new to that phase since 2018.
3.2. Phase 3
In phase 3, there are 28 agents in 42 trials (Figs. 1 and 2,
Table 1). There are 11 symptomatic agents in phase 3; three
cognitive enhancers and eight targeting behavioral symp-
toms. There are six biological therapies and 11 oral agents/
small molecules in phase 3 that target disease modification.
All the biological therapies and four of the small molecules
have amyloid as the primary or one of several targets. There
is one anti-tau agent in phase 3: LMTX (TRx0237). A phase
3 trial of this agent failed to show a drug-placebo difference
[19], and based on the results, a new phase 2/3 trial
(LUCIDITY) was started in 2018 with a lower dose of
LMTX as monotherapy. Other mechanisms represented
among phase 3 DMT molecules include neuroprotection,
anti-inflammatory approaches, and metabolic interventions.
Of the DMTs, two are repurposed agents approved for use in
another indication (losartan plus amlodipine plus atorvasta-
tin; and levetiracetam). Of the drugs with amyloid targets,
there were six biologics, two beta-site amyloid precursor
protein cleavage enzyme (BACE) inhibitors, and one anti-
aggregation agent. Fig. 2 shows the MOAs of agents in
phase 3.
There were six prevention trials enrolling cognitively
normal participants; 14 trials in patients with prodromal
AD/mild cognitive impairment (MCI) or prodromal-to-
mild AD; 12 trials of patients with mild-to-moderate AD;
and 10 trials of patients with mild-to-severe AD.
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Fig. 1. All compounds in AD clinical trials as of February 12, 2019 (the inner ring shows phase 3 agents; the middle ring is comprised of phase 2 agents; the
outer ring presents phase 1 compounds; agents in green areas are biologics; agents in purple areas are disease-modifying small molecules; agents in orange areas
are symptomatic agents addressing cognitive enhancement or behavioral and neuropsychiatric symptoms; the shape of the icon shows the population of the trial;
the icon color shows the class of target for the agent.). Bolded names represent agents new to that phase since 2018.
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Phase 3 trials included an average of 640 participants and
had a mean duration of 246 weeks (including the recruitment
and the treatment period). Mean treatment exposure period
was 73 weeks. DMT trials were longer and larger than trials
of symptomatic agents with a mean duration of 297 weeks
including 112 treatment weeks, and included an average of
862 participants. The mean duration of cognitive enhancer
trials was 88 weeks (17 treatment weeks), and they included
an average of 333 participants. Trials of agents for behav-
ioral symptoms had a mean duration of 187 weeks (15 treat-
ment weeks) and included a mean of 311 subjects.
The average duration of treatment exposure for phase 3
DMTs is 112 weeks, and themean period from trial initiation
to primary completion date (final data collection date for pri-
mary outcome measures) is 269 weeks. This indicates that
157 weeks, more than the treatment period, is the average
anticipated recruitment time. When examined by trial popu-
lation, DMT prevention trials are 405 weeks in duration (192
treatment weeks); trials for patients with MCI/prodromal/
prodromal-to-mild AD are 263 weeks in duration (98 treat-
ment weeks); and trials for patients with mild-to-moderate
AD are 264 weeks in duration (57 treatment weeks). Planned
recruitment periods for these three types of trials are 192,
130, and 191 weeks, respectively.
3.3. Phase 2
Phase 2 has a larger array of therapies and mechanisms
that are being assessed than are represented in phase 3. There
are 74 agents in 83 trials (Figs. 1 and 3, Table 2). Of these,
there are 20 symptomatic agents; 14 cognitive enhancers;
and six agents targeting behavioral symptoms. There are
53 potential disease-modifying agents in phase 2 trials; 16
biologics and 37 small molecules. One agent had an undis-
closed mechanism. Twelve of the small molecules and eight
of the biologics have amyloid reduction as one of the mech-
anisms observed in nonclinical studies (38% of DMTs). Four
small molecules and six biologics in phase 2 target tau as one
of their mechanisms (19% of DMTs). There are 24 small
molecules and two biologics with neuroprotection as one
of the mechanisms (49% of DMTs). Other mechanisms rep-
resented in phase 2 include anti-inflammatory and metabolic
interventions as the primary or one of a combination of ef-
fects documented in animal models. There are six trials
involving stem cell therapies. Sixteen of the DMT agents
are repurposed agents approved for use in another indication.
Of the drugs with amyloid targets, there were seven im-
munotherapies, one colony-stimulating factor, two BACE
inhibitors, and two alpha-secretase modulators. Two agents
targeted synaptic activity, two were anti-aggregation agents,
and two agents involved neuroprotection or a metabolic
MOA. There were two agents targeting both amyloid and
tau reduction. Fig. 3 shows the MOAs of agents in phase 2.
Three of the phase 2 trials were prevention trials; 36 trials
involved patients with prodromal or prodromal and mild
AD; 38 were trials for mild-to-moderate AD; two trials
were for patients with severe AD; two included patients
with mild, moderate, or severe AD; one included patients
withMCI or healthy volunteers; and one trial was for prodro-
mal or mild-to-moderate AD.
Phase 2 trials are shorter in duration and smaller in terms
of participant number than phase 3 trials; phase 2 trials had a
mean duration of 178 weeks, average treatment period of
45 weeks, and included an average of 143 subjects in each
trial.
3.4. Phase 1
Phase 1 has 30 agents in 31 trials (Fig. 1, Table 3).
There are two cognitive enhancers being assessed in phase 1.
Fig. 2. Mechanisms of action of agents in phase 3.
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Table 1
Agents currently in phase 3 of Alzheimer’s disease drug development (as of February 12, 2019)
Agent
Agent mechanism
class Mechanism of action Therapeutic purpose
ClinicalTrials.gov
ID Status Sponsor
Start
date
Estimated
end date
Aducanumab* Antiamyloid Monoclonal antibody
directed at plaque
and oligomers
Remove amyloid (DMT) NCT02484547 Active, not
recruiting
Biogen Sep 2015 Apr 2022
NCT02477800 Active, not
recruiting
Biogen Aug 2015 Apr 2022
AGB101 (low-dose
levetiracetam)
Neuroprotective SV2A modulator Decrease amyloid-induced
neuronal hyperactivity (DMT)
NCT03486938 Recruiting AgeneBio, NIA Jan 2019 Nov 2022
Plasma exchange
with albumin 1
immunoglobulin*
Antiamyloid Plasma exchange Remove amyloid (DMT) NCT01561053y Active, not
recruiting
Grifols Mar 2012 Dec 2017
ALZT-OP1a 1
ALZT-OP1b
(cromolyn 1
ibuprofen)
Antiamyloid,
anti-inflammatory
Mast cell stabilizer
(cromolyn),
anti-inflammatory
(ibuprofen)
Reduce neuronal damage; mast
cells may also play a role in
amyloid pathology (DMT)
NCT02547818 Recruiting AZTherapies, Pharma
Consulting Group,
KCAS Bio, APCER
Life Sciences
Sep 2015 Nov 2019
ANAVEX2-73 Anti-tau, antiamyloid,
anti-inflammatory
Sigma-1 receptor
agonist (high affinity),
muscarinic agonist
(low affinity),
GSK-3b inhibitor
Improve cell signaling (cognitive
enhancer) and reduce tau
phosphorylation and
amyloid (DMT)
NCT03790709y Recruiting Anavex Life Sciences Jul 2018 Mar 2021
AVP-786 Neurotransmitter based Sigma-1 receptor
agonist; NMDA
receptor antagonist
Improve neuropsychiatric
symptoms (agitation)
NCT02442765 Active, not
recruiting
Avanir Sep 2015 Apr 2019
NCT02442778 Recruiting Avanir Sep 2015 Dec 2019
NCT02446132 Recruiting,
extension
Avanir Dec 2015 Jun 2022
NCT03393520 Recruiting Avanir Oct 2017 Jun 2021
AXS-05 Neurotransmitter based Sigma-1 receptor agonist;
NMDA receptor
antagonist
(dextromethorphan);
dopamine-norepinephrine
reuptake inhibitor
(bupropion)
Improve neuropsychiatric
symptoms (agitation)
NCT03226522y Recruiting Axsome Therapeutics Jul 2017 Sep 2019
BHV4157
(troriluzole)
Neuroprotective Glutamate modulator Reduce synaptic levels of
glutamate (DMT)
NCT03605667y Recruiting Biohaven Pharma, ADCS Jul 2018 Feb 2020
Brexpiprazole Neurotransmitter based Atypical antipsychotic;
D2 receptor partial
agonist and serotonin-
dopamine modulator
Improve neuropsychiatric
symptoms (agitation)
NCT03620981y Recruiting Otsuka Aug 2018 Nov 2021
NCT03594123 Recruiting,
extension
Otsuka Oct 2018 Aug 2021
NCT03548584 Recruiting Otsuka May 2018 Dec 2020
NCT03724942 Recruiting,
extension
Otsuka Nov 2018 May 2021
CAD106 &
CNP520
Antiamyloid Amyloid vaccine
(CAD106), BACE
inhibitor (CNP520)
Remove amyloid (vaccine);
prevent amyloid
production (BACE
inhibitor) (DMT)
NCT02565511y Recruiting Novartis, Amgen, NIA,
Alzheimer’s Association,
Banner Alzheimer’s
Institute
Feb 2016 Jan 2025
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Table 1
Agents currently in phase 3 of Alzheimer’s disease drug development (as of February 12, 2019) (Continued )
Agent
Agent mechanism
class Mechanism of action Therapeutic purpose
ClinicalTrials.gov
ID Status Sponsor
Start
date
Estimated
end date
CNP520 Antiamyloid BACE inhibitor Prevent amyloid
production (DMT)
NCT03131453y Recruiting Novartis, Amgen, Banner
Alzheimer’s Institute
Aug 2017 Mar 2025
COR388 Anti-inflammatory Bacterial protease
inhibitor targeting
a periodontal pathogen
Reduce neuroinflammation
and hippocampal
degeneration (DMT)
NCT03823404y Not yet
recruiting
Cortexyme Apr 2019 Dec 2022
Crenezumab* Antiamyloid Monoclonal antibody
directed at oligomers
Remove amyloid (DMT) NCT02670083 Active, not
recruiting
Roche Mar 2016 Jul 2021
NCT03114657 Recruiting Roche Mar 2017 Oct 2022
NCT03491150 Recruiting,
extension
Roche Apr 2018 Nov 2022
E2609 (elenbecestat) Antiamyloid BACE inhibitor Reduce amyloid
production (DMT)
NCT02956486 Recruiting Eisai, Biogen Oct 2016 Jun 2021
NCT03036280 Recruiting Eisai, Biogen Dec 2016 Jun 2021
Escitalopram Neurotransmitter based Serotonin reuptake
inhibition
Improve neuropsychiatric
symptoms (agitation)
NCT03108846 Recruiting NIA, JHSPH Center
for Clinical Trials
Jan 2018 Aug 2022
Gantenerumab Antiamyloid Monoclonal antibody Remove amyloid (DMT) NCT02051608 Active, not
recruiting
Roche Mar 2014 Nov 2020
NCT01224106 Active, not
recruiting
Roche Nov 2010 Aug 2020
NCT03444870 Recruiting Roche Jun 2018 May 2023
NCT03443973 Recruiting Roche Jun 2018 May 2023
Gantenerumab &
Solanezumab
Antiamyloid Monoclonal antibody
directed at plaque
and oligomers
(gantenerumab);
Monoclonal antibody
directed at monomers
(solanezumab)
Remove amyloid/reduce
amyloid production (DMT)
NCT01760005y Active, not
recruiting
Washington University,
Eli Lilly, Roche, NIA,
Alzheimer’s Association
Dec 2012 Dec 2023
Ginkgo Biloba Metabolic Plant extract with
antioxidant properties
Improve brain blood flow and
mitochondrial function
(cognitive enhancer)
NCT03090516y Recruiting Nanjing Medical University Aug 2016 Mar 2018
Guanfacine Neurotransmitter based Alpha-2 adrenergic agonist Modulation of noradrenergic
deficit (cognitive enhancer)
NCT03116126 Not yet
recruiting
Imperial College London,
UK National Institute
of Health Research
Sep 2018 Sep 2019
Icosapent
ethyl (IPE)
Neuroprotective Purified form of the omega-3
fatty acid EPA
Protect neurons from disease
pathology (DMT)
NCT02719327y Recruiting VA Office of Research
and Development,
University of Wisconsin,
Madison
Jun 2017 Nov 2021
Losartan &
Amlodipine &
Atorvastatin 1
exercise
Anti-inflammatory,
metabolic
Angiotensin II receptor
blocker (losartan),
calcium channel blocker
(amlodipine), cholesterol
agent (atorvastatin)
Intensive vascular risk
reduction can preserve
cognitive function (DMT)
NCT02913664y Recruiting University of Texas
Southwestern
Sep 2016 Sep 2022
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Table 1
Agents currently in phase 3 of Alzheimer’s disease drug development (as of February 12, 2019) (Continued )
Agent
Agent mechanism
class Mechanism of action Therapeutic purpose
ClinicalTrials.gov
ID Status Sponsor
Start
date
Estimated
end date
Masitinib Anti-inflammatory Selective tyrosine kinase
inhibitor
Activity on mast cells,
modulation of inflammatory
processes (DMT)
NCT01872598 Active, not
recruiting
AB Science Jan 2012 Oct 2019
Methylphenidate Neurotransmitter based Dopamine reuptake
inhibitor
Improve neuropsychiatric
symptoms (apathy)
NCT02346201 Recruiting Johns Hopkins, NIA Jan 2016 Aug 2020
Mirtazapine Neurotransmitter based Alpha-1 antagonist Improve neuropsychiatric
symptoms (agitation)
NCT03031184 Recruiting University of Sussex Jan 2017 Jul 2020
Nabilone* Neurotransmitter based Cannabinoid
(receptor agent)
Improve neuropsychiatric
symptoms (agitation)
NCT02351882y Active, not
recruiting
Sunnybrook Health
Sciences Center
Jan 2015 Mar 2019
Octohydroaminoacridine
Succinate
Neurotransmitter based Acetylcholinesterase
inhibitor
Improve acetylcholine signaling
(cognitive enhancer)
NCT03283059 Recruiting Shanghai Mental
Health Center,
Changchun-Huayang
High-tech Co., Jiangsu
Sheneryang High-tech Co.
Aug 2017 Feb 2020
Solanezumab Antiamyloid Monoclonal antibody
directed at monomers
Remove amyloid and prevent
aggregation (DMT)
NCT02008357 Active, not
recruiting
Eli Lilly, ATRI Feb 2014 Jul 2022
TRx0237 (LMTX) Anti-tau Tau protein aggregation
inhibitor
Reduce tau-mediated neuronal
damage (DMT)
NCT03446001y Recruiting TauRx Therapeutics Jan 2018 Jun 2020
Zolpidem Neurotransmitter based Positive allosteric
modulator of
GABA-A receptors
Improve neuropsychiatric
symptoms (sleep disorders)
NCT03075241 Recruiting Brasilia University Hospital Oct 2016 Dec 2018
Abbreviations: ATRI, Alzheimer’s Therapeutic Research Institute; BACE, beta-site amyloid precursor protein cleaving enzyme; DMT, disease-modifying therapy; EPA, eicosapentaenoic acid; GABA, gamma-
aminobutyric acid; GSK, glycogen synthase kinase; NIA, National Institute on Aging; SV2A, synaptic vesicle protein 2A.
NOTE. Twenty-eight agents in 42 phase 3 clinical trials currently ongoing as of February 12, 2019 according to clinicaltrials.gov.
Bolded terms represent new agents into the 2019 phase 3 pipeline.
*Reported as terminated or completed after the data collection date of February 12, 2019.
yPhase 2/3 trials.
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There are currently no agents addressing neuropsychiatric
symptoms in phase 1. In addition, there are 13 small mole-
cules and 13 biologics being assessed in phase 1. The
MOA was not identified for two agents. Two of the small
molecules and six of the biologics have amyloid as a primary
target or one among several targets. Tau is targeted by one
small molecule and four biologics in phase 1 studies.
Other mechanisms represented in phase 1 include neuropro-
tection, metabolic, anti-inflammatory, and regenerative
interventions.
Phase 1 trials had an average duration of 141 weeks
(recruitment and treatment period) and included a mean
number of 58 participants in each trial.
3.5. Trial sponsors
Across all trials, 54% are sponsored by the biopharma in-
dustry, 35% by Academic Medical Centers (with funding
from NIH, industry, or other entities), and 10% by others.
Table 4 shows the sponsor of agents in each phase of devel-
opment.
3.6. Biomarkers
Table 5 shows the biomarkers used as outcome mea-
sures in current phase 2 and phase 3 AD clinical trials
as described in the federal website; not all trial descrip-
tions in clinicaltrials.gov note if biomarkers are included
in the trial.
AD biomarkers served as secondary outcome measures
in 16 phase 3 DMT trials and 29 phase 2 DMT trials. The
most common biomarkers used were cerebrospinal fluid
(CSF) amyloid, CSF tau, volumetric magnetic resonance
imaging, and amyloid PET. Of the 25 phase 3 DMT trials,
five trials (20%) used amyloid PET as an entry criterion,
two (8%) used CSF amyloid, and eight (32%) used either
amyloid PET or CSF amyloid. Ten (17%) out of 60 phase
2 DMT trials used amyloid PET as an entry criterion,
seven (12%) used CSF amyloid, and six (10%) used either
amyloid PET or CSF amyloid. Ten DMT trials in phase 3
and 37 in phase 2 did not require biomarker confirmation
of AD for trial entry.
Table 5. Biomarkers as outcome measures in phase 2 and
phase 3 trials for agents in the Alzheimer’s disease drug
development pipeline (clinicaltrials.gov as of February 12,
2019)
3.7. Devices
A variety of approaches to brain stimulation are under
study in clinical trials for AD (Table 6). These range from
deep brain stimulation with implanted electrodes to surface
application of light, electric current, and laser therapy. Most
of the trials target cognitive enhancement; a few trials posit
effects on amyloid, tau, inflammation, oxidative stress, or
mitochondrial function [20,21]. Targets have varied from
deep brain stimulation of fornix and memory-related struc-
tures to surface stimulation of parieto-frontal regions. The
few completed studies have shown no consistent cognitive
benefit; the techniques have been safe with acceptable
adverse event profiles [22]. There are no FDA-defined
phases for device trials, and most trials did not list the phase
on clinicaltrials.gov. The stages of development for device
studies can be divided into pilot, pivotal, and postapproval
phases.
4. Discussion
In 2018, the FDA approved 59 novel pharmacother-
apies across all therapeutic areas, breaking the 1996
Fig. 3. Mechanisms of action of agents in phase 2.
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Table 2
Agents currently in phase 2 of Alzheimer’s disease drug development (as of February 12, 2019)
Agent
Agent mechanism
class Mechanism of action Therapeutic purpose
ClinicalTrials.gov
ID Status Sponsor Start date
Estimated
end date
AADvac1 Anti-tau Active immunotherapy Remove tau and prevent
tau propagation (DMT)
NCT02579252 Active, not
recruiting
Axon Neuroscience Mar 2016 Jun 2019
ABBV-8E12 Anti-tau Monoclonal antibody Remove tau and prevent
tau propagation (DMT)
NCT02880956 Recruiting AbbVie Oct 2016 Sep 2022
NCT03712787 Not yet
recruiting,
extension
AbbVie Nov 2018 Aug 2027
ABvac40 Antiamyloid Active immunotherapy Remove amyloid (DMT) NCT03461276 Recruiting Araclon Biotech Feb 2018 Feb 2021
AD-35 Neurotransmitter
based
Acetylcholinesterase
inhibitor
Improve acetylcholine
signaling (cognitive
enhancer)
NCT03625401 Recruiting Zhejiang Hisun
Pharmaceutical,
Medpace, Inc.
Oct 2018 Jul 2020
NCT03790982 Active, not
recruiting
Zhejiang Hisun
Pharmaceutical
Dec 2018 Jul 2021
Aducanumab* Antiamyloid Monoclonal antibody
directed at plaque and
oligomers
Remove amyloid (DMT) NCT03639987 Recruiting Biogen Dec 2018 Nov 2023
AMX0035 Neuroprotective Blocks mitochondrial and
endoplasmic reticulum
stress
Blocks nerve cell death
and neuroinflammation
(DMT)
NCT03533257 Recruiting Amylyx Pharmaceuticals,
ADDF, Alzheimer’s
Association
Aug 2018 Sep 2020
ANAVEX 2-73 Anti-tau, antiamyloid,
anti-inflammatory
Sigma-1 receptor agonist
(high affinity);
muscarinic agonist
(low affinity); GSK-3b
inhibitor
Improve cell signaling
(cognitive enhancer)
and reduce tau
phosphorylation and
amyloid (DMT)
NCT02756858 Active, not
recruiting,
extension
Anavex Life Sciences Mar 2016 Nov 2020
APH-1105 Antiamyloid Alpha-secretase
modulator
Reduce amyloid (DMT) NCT03806478 Not yet
recruiting
Aphios Jun 2021 Dec 2022
AR1001 Antiamyloid PDE 5 inhibitor Improve synaptic
plasticity and reduce
amyloid (DMT)
NCT03625622 Recruiting AriBio Co. Jan 2019 Aug 2020
AstroStem Regenerative Stem cell therapy;
autologous adipose
tissue derived
mesenchymal stem
cells
Regenerate neurons
(DMT)
NCT03117738y Recruiting Nature Cell Co. Apr 2017 Jul 2019
BAC Undisclosed Undisclosed Undisclosed NCT02886494 Recruiting Charsire Biotechnology Dec 2016 Nov 2019
NCT02467413 Not yet
recruiting
Charsire Biotechnology,
A2 Healthcare Taiwan
Corporation
Dec 2019 Dec 2021
Benfotiamine Metabolic Synthetic thiamine (B1) Improve multiple cellular
processes (cognitive
enhancer)
NCT02292238 Recruiting Burke Medical Research
Institute, Columbia
University, NIA,
ADDF
Nov 2014 Nov 2019
(Continued )
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Table 2
Agents currently in phase 2 of Alzheimer’s disease drug development (as of February 12, 2019) (Continued )
Agent
Agent mechanism
class Mechanism of action Therapeutic purpose
ClinicalTrials.gov
ID Status Sponsor Start date
Estimated
end date
BI425809 Neurotransmitter
based
Glycine transporter 1
inhibitor
Facilitate NMDA receptor
activity (cognitive
enhancer)
NCT02788513 Recruiting Boehringer Ingelheim Aug 2016 Mar 2020
BIIB092 Anti-tau Monoclonal antibody Remove tau and reduce
tau propagation (DMT)
NCT03352557 Recruiting Biogen May 2018 Jul 2021
BPN14770 Anti-inflammatory PDE4D inhibitor Prolongs cAMP activity
(cognitive enhancer)
NCT03817684 Not yet
recruiting
Tetra Discovery Partners Apr 2019 Jun 2020
Byrostatin Metabolic Protein kinase C
modulator
Improve multiple cellular
processes (cognitive
enhancer)
NCT03560245 Recruiting Neurotrope Bioscience Jun 2018 Jul 2019
Candesartan Neuroprotective,
metabolic,
antiamyloid
Angiotensin receptor
blocker
Improve vascular
functioning and reduce
amyloid (DMT)
NCT02646982 Recruiting Emory University Jun 2016 Sep 2021
CERE-110* Neuroprotective Adeno-associated virus-
based gene delivery
vector of nerve growth
factor
Cholinergic neuronal
hypertrophy; slows
age-related
neurodegeneration
(DMT)
NCT00876863 Active, not
recruiting
Sangamo Therapeutics,
ADCS
Sep 2009 Mar 2020
Cilostazol Neuroprotective PDE-3 inhibitor Reduce accumulation of
amyloid and reduce tau
phosphorylation;
improve cerebral
circulation (DMT)
NCT02491268 Recruiting National Cerebral and
Cardiovascular Center,
Japan
Jul 2015 Dec 2020
Crenezumab* Antiamyloid Monoclonal antibody
targeting soluble
oligomers
Remove amyloid (DMT) NCT01998841 Active, not
recruiting
Genentech, NIA
Banner Alzheimer’s
Institute
Dec 2013 Feb 2022
CT1812 Antiamyloid Sigma-2 receptor
antagonist
Reduce amyloid-beta
protein-induced
synaptic toxicity
(DMT)
NCT03507790 Recruiting Cognition Therapeutics Oct 2018 Dec 2019
NCT03493282y Recruiting Cognition Therapeutics Apr 2018 Jan 2020
Curcumin 1
aerobic yoga
Neuroprotective Herb with antioxidant and
anti-inflammatory
properties
Reduce amyloid
production, decrease
neuroglial cell
proliferation (DMT)
NCT01811381 Recruiting VAOffice of Research and
Development
Jan 2014 Dec 2019
DAOI Neurotransmitter
based
NMDA receptor
modulation
Enhance NMDA activity
(cognitive enhancer)
NCT03752463 Recruiting Chang Gung Memorial
Hospital, Taiwan
May 2015 Dec 2019
Dapagliflozin Metabolic SGLT2 inhibitor Improve insulin
sensitivity (cognitive
enhancer)
NCT03801642y Recruiting University of Kansas Feb 2019 Oct 2020
(Continued )
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Table 2
Agents currently in phase 2 of Alzheimer’s disease drug development (as of February 12, 2019) (Continued )
Agent
Agent mechanism
class Mechanism of action Therapeutic purpose
ClinicalTrials.gov
ID Status Sponsor Start date
Estimated
end date
Deferiprone Antiamyloid,
neuroprotective
Iron chelating agent Reduce reactive oxygen
species that damage
neurons; effect on
amyloid and BACE
pathology (DMT)
NCT03234686 Recruiting Neuroscience Trials
Australia
Jan 2018 Dec 2021
DHA Neuroprotective Omega-3 fatty acid in high
concentration in the
brain
Reduce amyloid
production, improve
synaptic function
(DMT)
NCT03613844 Recruiting University of Southern
California
Jul 2018 Sep 2024
DHP1401 Metabolic Affects cAMP activity Improve synaptic function
(cognitive enhancer)
NCT03055741 Active, not
recruiting
Daehwa
Pharmaceutical Co.
Dec 2016 Jun 2019
Dronabinol Neurotransmitter
based
CB1 and CB2
endocannabinoid
receptor partial agonist
Improve neuropsychiatric
symptoms (agitation)
NCT02792257 Recruiting Mclean Hospital, Johns
Hopkins University
Mar 2017 Dec 2020
E2609
(elenbecestat)
Antiamyloid BACE inhibitor Reduce amyloid
production (DMT)
NCT02322021 Active, not
recruiting
Eisai, Biogen Nov 2014 Jun 2020
Elderberry Juice Anti-inflammatory,
neuroprotective
Antioxidant rich in
anthocyanins
Improve mitochondrial
function (DMT)
NCT02414607y Recruiting University of Missouri Sep 2016 Apr 2019
Formoterol Metabolic Beta-2 adrenergic
receptor agonist
Effects on multiple
cellular pathways
(DMT)
NCT02500784 Recruiting Palo Alto Veterans
Institute for Research,
Mylan,
Alzheimer’s
Association
Jan 2015 Jul 2018
Grapeseed Extract Neuroprotective Polyphenolic compounds;
antioxidant
Anti-oligomerization
agent; prevents
aggregation of amyloid
and tau (DMT)
NCT02033941 Recruiting Mount Sinai School of
Medicine, NCCIH
Nov 2014 Sep 2018
GRF6019 Anti-inflammatory Human plasma protein
fraction infusions
Young blood parabiosis
can counteract
inflammatory and age-
related processes in the
brain (DMT)
NCT03520998 Recruiting Alkahest Apr 2018 Nov 2019
NCT03765762 Recruiting Alkahest Dec 2018 Nov 2019
GV1001 Antiamyloid,
metabolic
Telomerase reverse
transcriptase peptide
vaccine
Effects on multiple
cellular pathways
including amyloid
pathology (DMT)
NCT03184467 Recruiting GemVax & Kael Jun 2017 Jun 2019
(Continued )
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Table 2
Agents currently in phase 2 of Alzheimer’s disease drug development (as of February 12, 2019) (Continued )
Agent
Agent mechanism
class Mechanism of action Therapeutic purpose
ClinicalTrials.gov
ID Status Sponsor Start date
Estimated
end date
hUCB-MSCs Regenerative Stem cell therapy Regenerate neurons;
reduce amyloid plaque
deposition and soluble
amyloid; decrease
microglial systemic
inflammation (DMT)
NCT02054208y Recruiting Medipost Co. Feb 2014 Jul 2019
NCT03172117y Recruiting,
extension
Medipost Co. May 2017 Dec 2021
NCT02513706 Ongoing South China Research
Center
Oct 2017 Oct 2019
NCT02672306y Ongoing South China Research
Center
Oct 2017 Oct 2019
NCT02833792 Active, not
recruiting
Stemedica Cell
Technologies
Jun 2016 Jun 2020
ID1201 Antiamyloid Alpha-secretase enhancer Reduce amyloid (DMT) NCT03363269 Ongoing IlDong Pharmaceutical Apr 2016 Dec 2018
Insulin glulisine
(intranasal)
Metabolic Increase insulin signaling
in the brain
Enhance cell signaling
and growth; promote
neuronal metabolism
(DMT)
NCT02503501 Ongoing HealthPartners Institute Aug 2015 May 2019
IONIS MAPTRx
(BIIB080)
RNA-based anti-tau MAPT RNA inhibitor;
antisense
oligonucleotide
Reduce tau production
(DMT)
NCT03186989y Recruiting Ionis Pharmaceuticals,
Biogen
Jun 2017 Feb 2020
Lemborexant Neurotransmitter
based
Dual antagonist of orexin
OX1 and OX2
receptors
Improve neuropsychiatric
symptoms (sleep
disorders)
NCT03001557 Active, not
recruiting
Eisai, Purdue Dec 2016 Apr 2020
Levetiracetam Neuroprotective SV2A modulator Decrease amyloid-
induced neuronal
hyperactivity (DMT)
NCT02002819 Recruiting University of California,
San Francisco
Jun 2014 Dec 2019
NCT03489044 Recruiting University of Oxford,
NHS Foundation Trust,
UCB Pharma
Nov 2018 Jan 2020
NCT03461861 Recruiting Medical College of
Wisconsin, NIA
Nov 2018 Mar 2019
Liraglutide Metabolic Glucagon-like peptide 1
receptor agonist
Enhance cell signaling
(cognitive enhancer)
NCT01843075 Recruiting Imperial College London Jan 2014 Mar 2019
Lithium Neurotransmitter
based
Ion channel modulator Improve neuropsychiatric
symptoms (agitation,
mania, psychosis)
NCT02129348 Recruiting New York State
Psychiatric Institute,
NIA
Jun 2014 Apr 2019
LM11A-31-BHS Neuroprotective p75 neurotrophin
receptor ligand
Inhibits tau
phosphorylation and
synaptic dysfunction;
prevents amyloid-
induced toxicity
(DMT)
NCT03069014y Recruiting PharmatrophiX Inc.,
NIA
Feb 2017 Oct 2019
Lupron
(leuprolide
acetate depot)
Metabolic Gonadotropin-releasing
hormone receptor
agonist
Suppresses brain-
produced
gonadotropin-releasing
hormone (cognitive
enhancer)
NCT03649724 Not yet
recruiting
New York University Dec 2018 Dec 2020
(Continued )
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Table 2
Agents currently in phase 2 of Alzheimer’s disease drug development (as of February 12, 2019) (Continued )
Agent
Agent mechanism
class Mechanism of action Therapeutic purpose
ClinicalTrials.gov
ID Status Sponsor Start date
Estimated
end date
L-Serine Neuroprotective Amino acid Stabilizes protein
misfolding (DMT)
NCT03062449 Recruiting Dartmouth-Hitchcock
Medical Center, Brain
Chemistry
Laboratories
Mar 2017 Aug 2019
LY3002813 Antiamyloid Monoclonal antibody Remove amyloid (DMT) NCT03367403 Recruiting Eli Lilly Dec 2017 Sep 2021
LY3303560 Anti-tau Monoclonal antibody Remove tau and reduce
tau propagation (DMT)
NCT03518073 Recruiting Eli Lilly Apr 2018 Oct 2021
Methylene blue Anti-tau Tau protein aggregation
inhibitor
Reduce neurofibrillary
tangle formation
(DMT)
NCT02380573 Active, not
recruiting
Texas Alzheimer’s
Research and Care
Consortium
Jul 2015 Jul 2019
MLC901
(NeuroAiD)
Neuroprotective,
anti-inflammatory
Traditional Chinese
medicine consisting
of several herbs
Multiple cellular
pathways (DMT)
NCT03038035 Recruiting National University
Hospital, Singapore
Dec 2016 Jun 2019
Montelukast Anti-inflammatory Leukotriene receptor
antagonist
Reduce inflammatory
pathways (cognitive
enhancer)
NCT03402503 Recruiting IntelGenx Corp. Nov 2018 Oct 2020
MP-101 Neurotransmitter
based
Enhance mitochondrial
functioning
Improve neuropsychiatric
symptoms (psychosis)
NCT03044249 Recruiting Mediti Pharma May 2017 Jan 2021
NA-831
(traneurocin)
Neuroprotective Undisclosed Neurogenesis and
neuroprotection
(DMT)
NCT03538522 Not yet
recruiting
NeuroActiva Sep 2018 Apr 2019
Neflamapimod
(VX-745)
Anti-inflammatory Selective p38 MAPK
inhibitor
Affects multiple cellular
processes including
inflammation and
cellular plasticity;
reduces amyloid plaque
burden (DMT)
NCT03402659 Recruiting EIP Pharma, VU
University
Dec 2017 Jul 2019
NCT03435861 Recruiting EIP Pharma, Toulouse
University, Foundation
Plan Alzheimer
Oct 2018 Jan 2021
Nicotinamide Anti-tau,
neuroprotective
Histone deacetylase
inhibitor
Reduce tau-induced
microtubule
depolymerization
(DMT)
NCT03061474 Recruiting University of California,
Irvine
Jul 2017 Feb 2019
Nicotine Neurotransmitter
based
Nicotinic acetylcholine
receptor agonist
Enhance acetylcholine
signaling (cognitive
enhancer)
NCT02720445 Recruiting Univ. of Southern
California, NIA, ATRI,
Vanderbilt University
Jan 2017 Dec 2019
Nilotinib Antiamyloid, anti-tau Tyrosine kinase inhibitor Reduce amyloid and tau
phosphorylation
(DMT)
NCT02947893 Active, not
recruiting
Georgetown University Jan 2017 Dec 2019
Octagam 10% Antiamyloid 10% human normal
immunoglobulin
Remove amyloid (DMT) NCT03319810 Recruiting Sutter Health Jan 2018 May 2019
(Continued )
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Table 2
Agents currently in phase 2 of Alzheimer’s disease drug development (as of February 12, 2019) (Continued )
Agent
Agent mechanism
class Mechanism of action Therapeutic purpose
ClinicalTrials.gov
ID Status Sponsor Start date
Estimated
end date
Omega-3 PUFA Neuroprotective Fish oil concentrate
standardized to long
chain in n-3 PUFA
content
Support small blood
vessels in the brain
(DMT)
NCT01953705 Active, not
recruiting
Oregon Health and
Science University,
NIA
May 2014 Sep 2019
Pimavanserin Neurotransmitter
based
5-HT2A inverse agonist Improve neuropsychiatric
symptoms (psychosis)
NCT03118947 Active, not
recruiting,
extension
Acadia Feb 2017 Aug 2019
Piromelatine Neurotransmitter
based
Melatonin receptor
agonist; 5-HT 1A and
1D serotonin receptor
agonist
Enhance cellular signaling
(cognitive enhancer)
NCT02615002 Recruiting Neurim Pharmaceuticals Nov 2015 Apr 2019
Posiphen Antiamyloid Selective inhibitor of APP
production
Reduce amyloid
production (DMT)
NCT02925650y Recruiting QR Pharma, ADCS Mar 2017 Dec 2019
Prazosin Neurotransmitter
based
Alpha-1 adrenoreceptor
antagonist
Improve neuropsychiatric
symptoms (agitation)
NCT03710642 Recruiting ADCS, NIA Jan 2019 Dec 2022
PTI-125 Neuroprotective,
anti-inflammatory
FLNA inhibitor Reduce amyloid,
prevent tau
hyperphosphorylation
and inflammatory
toxicity (DMT)
NCT03748706 Recruiting Pain Therapeutics, NIH Nov 2018 Mar 2019
Rasagiline* Antiamyloid,
neuroprotective,
metabolic
Monoamine oxidase B
inhibitor
Enhance mitochondria
activity and inactivate
reactive oxygen species
(cognitive enhancer),
also effect on amyloid
pathology (DMT)
NCT02359552 Active, not
recruiting
The Cleveland Clinic May 2015 Feb 2019
Riluzole Neuroprotective Glutamate receptor
antagonist
Inhibit glutamate
neurotransmission
(DMT)
NCT01703117 Recruiting Rockefeller University Nov 2013 Nov 2019
RO7105705
(MTAU9937 A)
Anti-tau Monoclonal antibody Remove tau (DMT) NCT03289143 Recruiting Genentech Oct 2017 Sep 2022
NCT03828747 Recruiting Genentech Feb 2019 Sep 2021
RPh201 Neuroprotective Undisclosed Promote neurogenesis
(DMT)
NCT03462121 Recruiting Regenera Pharma Mar 2018 Apr 2019
Sargramostim*
(GM-CSF)
Antiamyloid,
neuroprotective
Synthetic granulocyte
colony stimulator
Stimulate innate immune
system to remove
amyloid pathology;
increase neuronal
connectivity (DMT)
NCT01409915 Active, not
recruiting
University of Colorado,
Denver,
The Dana Foundation
Mar 2011 Nov 2019
(Continued )
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Table 2
Agents currently in phase 2 of Alzheimer’s disease drug development (as of February 12, 2019) (Continued )
Agent
Agent mechanism
class Mechanism of action Therapeutic purpose
ClinicalTrials.gov
ID Status Sponsor Start date
Estimated
end date
S-equol
(AUS-131)
Neuroprotective Nonhormonal estrogen
receptor B agonist
Mitochondrial function
potentiation; improve
synaptic functioning,
protects neurons
(DMT)
NCT03101085y Recruiting Ausio Pharmaceuticals,
University of Kansas
May 2017 Oct 2019
SUVN-502 Neurotransmitter
based
5-HT 6 antagonist Improve neuronal
signaling (cognitive
enhancer)
NCT02580305 Active, not
recruiting
Suven Life Sciences Sep 2015 May 2019
Telmisartan &
Perindopril
Neuroprotective,
anti-inflammatory
Angiotensin II receptor
blocker, PPAR-gamma
agonist (telmisartan);
angiotensin converting
enzyme inhibitor
(perindopril)
Improve vascular
functioning (DMT)
NCT02085265 Recruiting Sunnybrook Health
Sciences Center,
ADDF
Mar 2014 Mar 2021
TEP Antiamyloid Antiemetic; activates
transport protein
ABCC1
Remove amyloid (DMT) NCT03417986 Recruiting Immungenetics AG Nov 2017 Jul 2021
UB-311 Antiamyloid Active immunotherapy Reduce amyloid (DMT) NCT03531710 Recruiting,
extension
United Neuroscience Aug 2018 Mar 2021
Valacyclovir Neuroprotective,
anti-inflammatory
Antiviral agent Protects against HSV-1/2
infection and
inflammation (DMT)
NCT02997982 Recruiting Umea University Dec 2016 Apr 2019
NCT03282916 Recruiting New York State
Psychiatric Institue,
NIH, NIA
Feb 2018 Aug 2022
Xanamem
(UE2343)
Neuroprotective Blocks 11 beta-HSD1
enzyme activity
Decrease cortisol
production and
neurodegeneration
(DMT)
NCT02727699 Active, not
recruiting
Actinogen Mar 2017 Jul 2019
Abbreviations: ABCC1, ATP binding cassette subfamily Cmember 1; ADCS, Alzheimer’s Disease Cooperative Study; ADDF, Alzheimer’s Drug Discovery Foundation; AMPA, a-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid; APOE, apolipoprotein E; APP, amyloid precursor protein; ATRI, Alzheimer’s Therapeutic Research Institute; BACE, beta-site amyloid precursor protein cleaving enzyme; cAMP,
cycling adenosine monophosphate; CB, cannabinoid; DHA, docosahexaenoic acid; DMT, disease-modifying therapy; FLNA, Filamin A; GM-CSF, granulocyte-macrophage colony-stimulating factor; GSK,
glycogen synthase kinase; HSD, hydroxysteroid dehydrogenase; HT, hydroxytriptamine; hUCB-MSCs, human umbilical cord blood derived mesenchymal stem cells; MAPK, mitogen-activated protein kinase;
MAPT, microtubule-associated tau; NCCIH, National Center for Complementary and Integrative Health; NIA, National Institute on Aging; NMDA, N-methyl-D-aspartate; PDE, phosphodiesterase; PPAR, perox-
isome proliferator-activated receptor; PUFA, polyunsaturated fatty acids; SGLT2, sodium-glucose transporter 2; SV2A, synaptic vesicle protein 2A; TEP, thiethylperazine.
NOTE. Seventy-four agents in 83 phase 2 clinical trials currently ongoing as of February 12, 2019 according to clinicaltrials.gov.
Bolded terms represent new agents into the 2019 phase 2 pipeline.
*Reported as terminated or completed after the data collection date of February 12, 2019.
yPhase 1/2 trials.
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Table 3
Agents currently in phase 1 of Alzheimer’s disease drug development (as of February 12, 2019)
Agent
Agent mechanism
class Mechanism of action Therapeutic purpose
ClinicalTrials.gov
ID Status Sponsor Start date
Estimated
end date
AAVrh.10hAPOE2 Neuroprotective Serotype rh. 10 adeno-
associated virus gene
transfer vector
expressing the cDNA
coding for human
ApoE2
Conversion of the ApoE
protein isoforms in the CSF
of ApoE4 homozygotes
from ApoE4 to ApoE2-
ApoE4 (DMT)
NCT03634007 Not yet recruiting Cornell University Jan 2019 Dec 2021
Aducanumab* Antiamyloid Monoclonal antibody Remove amyloid (DMT) NCT01677572 Active, not recruiting Biogen Oct 2012 Oct 2021
AL002 Anti-
inflammatory
Monoclonal antibody
targeting TREM2
receptors
Prevents inflammatory
activity (DMT)
NCT03635047 Recruiting Alector Nov 2018 Mar 2020
AL003 Anti-
inflammatory
Monoclonal antibody
targeting SIGLEC-3
Reactivates microglia and
immune cells in the brain
(DMT)
NCT03822208 Not yet recruiting Alector Mar 2019 Jul 2020
Allopregnanolone
(Allo-IM)
Neuroprotective,
metabolic
GABA receptor
modulator
Improve neurogenesis (DMT) NCT03748303 Not yet recruiting University of Southern
California, University of
Arizona, Alzheimer’s
Association
Dec 2018 Dec 2020
BDPP (bioactive
dietary polyphenol
preparation)
Neuroprotective Combination of
grape seed
polyphenolic extract
and resveratrol
Prevents amyloid and tau
aggregation (DMT)
NCT02502253 Recruiting Johns Hopkins University,
Mount Sinai School of
Medicine
Jun 2015 Oct 2019
BIIB076 Anti-tau Monoclonal antibody Remove tau and reduce tau
propagation (DMT)
NCT03056729 Recruiting Biogen Feb 2017 Jul 2019
CKD-355 Undisclosed Undisclosed Undisclosed NCT03802162 Not yet recruiting Chong Kun Dang
Pharmaceutical
Feb 2019 Jul 2019
Crenezumab* Antiamyloid Monoclonal antibody
targeting oligomers
Remove amyloid (DMT) NCT02353598 Active, not recruiting Genentech Feb 2015 Sep 2023
CT1812 Antiamyloid Sigma-2 receptor
antagonist
Reduce amyloid-beta protein-
induced synaptic toxicity
(DMT)
NCT03522129 Recruiting Cognition Therapeutics May 2018 Dec 2019
Dabigatran Neuroprotective Direct thrombin
inhibitor;
anticoagulant
Reduce neurovascular
damage (DMT)
NCT03752294 Not yet recruiting University of Rhode Island,
ADDF, Boehringer
Ingelheim
Nov 2018 Dec 2021
DNL747 Neuroprotective,
anti-
inflammatory
RIPK1 inhibitor Reduce cytokines and other
inflammatory factors
(DMT)
NCT03757325 Recruiting Denali Therapeutics Feb 2019 Aug 2019
Efavirenz Antiamyloid Antiretroviral;
nonnucleoside reverse
transcriptase inhibitor
Increase cholesterol removal
and enhance amyloid
reduction (DMT)
NCT03706885 Recruiting Case Western Reserve
University, Cleveland
Medical Center,
Massachusetts General
Hospital
Dec 2018 May 2020
Escitalopram &
Venlafaxine
Neurotransmitter
based
SSRI, SNRI Improve neurotransmission
(cognitive enhancer)
NCT03274817 Recruiting New York University Jul 2017 Jan 2019
hMSCs (human
mesenchymal
stem cells)
Regenerative Stem cell therapy Regenerate neurons NCT02600130 Recruiting Longeveron Aug 2016 Mar 2020
(Continued )
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Table 3
Agents currently in phase 1 of Alzheimer’s disease drug development (as of February 12, 2019) (Continued )
Agent
Agent mechanism
class Mechanism of action Therapeutic purpose
ClinicalTrials.gov
ID Status Sponsor Start date
Estimated
end date
Insulin aspart
(intranasal)
Metabolic Increase insulin
signaling in
the brain
Neuroprotection and
enhanced neuronal
function; protects against
amyloid toxicity (DMT)
NCT02462161 Recruiting Wake Forest School of
Medicine, NIA, General
Electric
May 2015 Sep 2019
J147 Neuroprotective Mitochondrial ATP
synthase inhibitor
Protects neurons from
multiple toxicities
associated with aging
(DMT)
NCT03838185 Recruiting Abrexa Jan 2019 Jan 2020
JNJ-63733657 Anti-tau Monoclonal antibody Remove tau and reduce tau
propagation (DMT)
NCT03375697 Recruiting Janssen Dec 2017 Oct 2019
Lu AF20513 Antiamyloid Active immunotherapy Remove amyloid (DMT) NCT02388152 Active, not recruiting Lundbeck Mar 2015 Dec 2019
NCT03668405 Recruiting, extension Lundbeck Jun 2018 Nov 2020
NCT03819699 Recruiting Lundbeck Dec 2018 Jun 2019
LY3002813 Antiamyloid Monoclonal antibody Remove amyloid (DMT) NCT02624778 Active, not recruiting Eli Lilly Dec 2015 May 2020
LY3303560 Anti-tau Monoclonal antibody Remove tau and reduce tau
propagation (DMT)
NCT03019536 Active, not recruiting Eli Lilly Jan 2017 Jun 2020
LY3372993 Antiamyloid Monoclonal antibody Remove amyloid (DMT) NCT03720548 Recruiting Eli Lilly Nov 2018 Sep 2021
MK-4334 Undisclosed Undisclosed Undisclosed NCT03740178 Not yet recruiting Merck Jan 2019 Jun 2019
NDX-1017 Regenerative Hepatocyte growth factor Regenerate neurons (DMT) NCT03298672 Recruiting M3 Biotechnology, ADDF,
Biotrial Inc.
Oct 2017 Apr 2019
NPT088 Antiamyloid,
anti-tau
IgG1-Fc-GAIM fusion
protein
Clear amyloid and tau (DMT) NCT03008161 Active, not recruiting Proclara Biosciences,
Alzheimer’s Association
Dec 2016 Apr 2019
Salsalate Anti-
inflammatory
Nonsteroidal anti-
inflammatory
Reduce neuronal injury
(DMT)
NCT03277573 Recruiting University of California, San
Francisco
Jul 2017 Oct 2019
Telmisartan Neuroprotective,
anti-
inflammatory
Angiotensin II receptor
blocker, PPAR-
gamma agonist
Improve vascular functioning
and effects on amyloid
pathology (DMT)
NCT02471833 Recruiting Emory University Apr 2015 Apr 2019
THN201 Neurotransmitter
based
Cholinesterase
inhibitor 1
antimalarial glial cell
modulator
Improve acetylcholine
signaling and modulate
astrocyte function (DMT)
NCT03698695 Recruiting Theranexus Sep 2018 Jul 2019
TPI-287 Anti-tau Microtubule protein
modulator
Reduce tau-mediated cellular
damage (DMT)
NCT01966666 Active, not recruiting University of California, San
Francisco
Nov 2013 Mar 2019
Vorinostat Neuroprotective Histone deacetylase
inhibitor
Enhance multiple cellular
processes including tau
aggregation and amyloid
deposition (DMT)
NCT03056495 Recruiting German Center for
Neurodegenerative
Diseases, University
Hospital, Bonn, University
of Gottingen
Sep 2017 Oct 2019
Abbreviations: ADDF, Alzheimer’s Drug Discovery Foundation; ApoE, apolipoprotein E; BACE, beta-site amyloid precursor protein cleaving enzyme; CSF, cerebrospinal fluid; DMT, disease-modifying ther-
apy; GABA, gamma-aminobutyric acid; GAIM, general amyloid interaction motif; NIA, National Institute on Aging; PPAR, peroxisome proliferator-activated receptor; RIPK1, receptor-interacting serine/thre-
onine-protein kinase 1; SIGLEC-3, sialic acid-binding Ig-like lectin 3; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; TREM2, triggering receptor expressed on
myeloid cells 2.
NOTE. Thirty agents in 31 phase 1 clinical trials currently ongoing as of February 12, 2019 according to clinicaltrials.gov.
Bolded terms represent new agents into the 2019 phase 1 pipeline.
*Reported as terminated or completed after the data collection date of February 12, 2019.
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record of 53 drug approvals [23,24]. There were 42 small
molecule therapies and 17 biological therapies approved
[24]. Eight new neurological drugs were included among
the new therapies: 3 migraine treatments (all were calci-
tonin gene-related peptide receptor antibodies), 2 for sei-
zures in Dravet syndrome (1 included Dravet syndrome
and Lennox-Gastaut syndrome), two for hereditary
transthyretin-mediated amyloidosis, and 1 for Fabry dis-
ease. The latter three agents can be regarded as DMTs,
the others provide relief of symptoms albeit life-
threatening symptoms in the case of the epilepsies. The
therapies for transthyretin-mediated amyloidosis are
RNA-based interventions (antisense oligonucleotide or
interference RNA) representing a new approach to neuro-
logical disorders. Oligonucleotide-based therapies have
shown initial promise in Huntington’s disease and may
have applications in other neurodegenerative disorders
including AD [25]. There is one RNA-based treatment
in the AD pipeline (IONIS MAPTRx).
Several agents have completed clinical trials since the
time of last year’s pipeline analysis and shown no drug-
placebo difference. LTMX targeted tau pathology in AD
and did not establish efficacy [19]. Azeliragon is a receptor
for advanced glycation end products inhibitor and was found
to produce no drug-placebo difference in a trial of mild-to-
moderate AD. Crenezumab is a monoclonal antibody that
targeted oligomeric forms of amyloid-beta protein (Ab)
[26]. It failed to show a drug-placebo difference at the
time of a futility analysis in two large clinical trials, and
development of the agent was halted. Similarly, aducanumab
trials were recently stopped after a futility analysis. Verube-
cestat is a BACE inhibitor whose development was halted
for futility in a mild-to-moderate AD clinical trial [27]. A
trial of verubecestat in patients with prodromal AD defined
by clinical and amyloid PET measures was halted after a fu-
tility analysis suggested that the agent could not succeed.
Similarly, lanabecestat did not meet the criteria to continue
after a futility analysis. Atabecestat is a BACE inhibitor be-
ing assessed in preclinical AD; the trial was discontinued
when elevated liver enzymes were observed among some
trial participants. Intranasal insulin was assessed in mild-
to-moderate AD and showed no drug-placebo difference
[28]. Pioglitazone, an insulin sensitizing agent was stopped
for futility in a preclinical AD trial. A trial of a FYN inhibitor
(AZD0530) used fluorodeoxyglucose PET as the primary
outcome and showed no drug-placebo difference on the
biomarker or any clinical measure [29]. Fluorodeoxyglucose
PET performed well in this multisite trial suggesting it can
be used in multicenter trials to show drug-placebo differ-
ences with agents that affect brain metabolism. ITI-007 is
a multitransmitter agent being developed for the treatment
of schizophrenia and was tested in a clinical trial to deter-
mine its effect on agitation in AD. No drug-placebo differ-
ence was observed in the trial. Of the 17 phase 3 DMTs
listed in our 2018 review, eight have been terminated.
GV-971 is a multitargeted molecule that completed a
phase 3 clinical trial in China in 2018 [30]. GV-971 has
nonclinical evidence of effects on neuroinflammation, amy-
loid plaques, neurofibrillary tangles, mitochondrial function,
and cholinergic function [30]. In a phase 3 trial conducted in
China by an international contract research organization,
GV-971 showed a statistically significant benefit over pla-
cebo on the Alzheimer’s Disease Assessment Scale–
cognitive subscale [31]; a trend toward improvement was
noted on the clinical interview-based impression of change
[32]. Therewas no impact on functional and behavioral mea-
sures. The outcomes appear to have met the criteria required
for approval by the Chinese FDA, and the agent is under re-
view.
Biomarkers play an increasingly important role in AD
drug development. Participant selection, target engagement,
disease course prediction, evidence of disease modification,
and side effect monitoring all involve biomarkers [33]. The
NIA–Alzheimer’s Association established the biomarker-
Table 4
Trial sponsor for each phase of development (clinicaltrials.gov as of
February 12, 2019)
Sponsor
N of trials (%)
Phase 1 Phase 2 Phase 3
Biopharma 18 (58) 39 (47) 28 (67)
Academic Medical Centers 8 (26) 20 (24) 7 (17)
NIH 0 0 0
NIH and Academic Medical Centers 0 5 (6) 2 (5)
NIH and Industry 0 2 (2) 1 (2)
Consortium/foundation 0 2 (2) 0
Industry and consortium/foundation 2 (6) 5 (6) 2 (5)
Academic Medical Centers and
consortium/foundation
1 (3) 2 (2) 0
Industry, Academic Medical
Centers, and consortium/foundation
2 (6) 2 (2) 0
Other combinations 0 6 (7) 2 (5)
Abbreviation: NIH, National Institutes of Health.
Table 5
Biomarkers as outcome measures in phase 2 and phase 3 trials for agents in
the Alzheimer’s disease drug development pipeline (clinicaltrials.gov as of
February 12, 2019)
Biomarker
N of trials (%)
Phase 3 Phase 2
CSF amyloid 14 (33) 15 (18)
CSF tau 13 (31) 17 (20)
FDG-PET 1 (2) 10 (12)
vMRI 10 (24) 8 (10)
Plasma amyloid 5 (12) 5 (6)
Plasma tau 2 (5) 1 (1)
Amyloid PET 11 (26) 6 (7)
Tau PET 8 (19) 2 (2)
Abbreviations: CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; PET,
positron emission tomography; vMRI, volumetric magnetic resonance
imaging.
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Table 6
Devices in clinical trials for treatment of Alzheimer’s disease (as of February 12, 2019)
Device Mechanism of action Clinicaltrials.gov ID Sponsor
tDCS Low intensity electric current to modulate
cortical excitability and brain plasticity
NCT02772185 Federal University of Paraiba, Brazil
NCT03638284 Center for Addiction and Mental Health
NCT03288363 Centre Hospitalier Esquirol
NCT02873546 Centre Hospitalier Universitaire de Besancon
NCT02155946 VA Office of Research and Development
Transcranial alternating
current stimulation
(tACS)
Gamma frequency stimulation to the region of
maximum amyloid burden; microglia
activation and decrease amyloid and tau
depositions
NCT03290326,
NCT03412604
Beth Israel Deaconess Medical Center
SonoCloud Low intensity contact ultrasound implant to open
the blood-brain barrier; allows increased
intracerebral bioavailability of anti-AD drugs;
may also allow endogenous antibodies to
penetrate the brain parenchyma and target
amyloid plaques even without any adjunct
antiamyloid treatment
NCT03119961 CarThera
MemorEM 1000 Transcranial electromagnetic treatment;
disaggregation of toxic oligomers;
mitochondrial enhancement
NCT02958930 NeuroEm Therapeutics
Neuro Gamma Photobiomodulation–administers low energy,
near-infrared LED light to the brain
transcranially and intranasally; reduces
oxidative stress and neuroinflammation
NCT03484143,
NCT03328195
Vielight
NCT03160027,
NCT03405662
University of California, San Francisco
RGn530 Photobiomodulation device; reduces oxidative
stress and neuroinflammation
NCT03672474 University Hospital, Montpellier (device by
REGEnLIFE)
Electroconvulsive therapy Improve cognition by increasing brain-derived
neurotrophic factor levels
NCT02438202 Central Institute of Mental Health, Mannheim
ExAblate Model 4000 Blood-brain barrier disruption by focal
ultrasound
NCT03671889,
NCT03739905
InSightec
GammaSense stimulation
system
Visual sensory stimulation device flickering
lights at gamma frequency to drive gamma
oscillations in brain areas; increase cerebral
blood flow and reduce amyloid
NCT03556280 Cognito Therapeutics
NCT03543878 Emory University, Georgia Institute of
Technology
Low level laser therapy Modulate cellular metabolism and regeneration NCT02537626 Erchonia Corporation
DBS Directly target and modulate the activity of brain
structures implicated in memory functioning;
improve cognition
NCT03347084 University of California, Los Angeles
NCT03352739 Xuanwu Hospital, China, Beijing Pins Medical
Co.
NCT03622905 Functional Neuromodulation
NCT03290274 Hospital San Carlos, Madrid
rTMS Stimulate different areas of the brain to induce
changes in brain activity and modify impaired
neural networks
NCT03121066 Universitat Oberta de Catalunya
NCT02908815 University of Manitoba
NCT03270137 Instituto Nacional de Psipquiatria Dr. Ramon de
la Fuente
NCT02190084 Central Arkansas Veterans Healthcare System
NCT03778151 Fondazione Santa Lucia
NEUROLITH TPS consisting of short acoustic pulses with an
ultrasound frequency to stimulate the brain;
maintains and improves cognitive abilities
NCT03770182 Storz Medical
tVNS Stimulation of the auricular branch with
electrodes on the external ear to improve
cognition
NCT03359902 University of Florida, NIA
NeuroAD Combination of TMS and cognitive training;
stimulates areas of the brain responsible for
cognitive functions that have been impaired by
AD and makes them more receptive to
cognitive training
NCT01825330 Neuronix
Abbreviations: AD, Alzheimer’s disease; DBS, deep brain stimulation; rTMS, repetitive transcranial magnetic stimulation; tDCS, Transcranial direct current
stimulation; tACS, Transcranial alternating current stimulation; TMS, transcranial magnetic stimulation; TPS, Transcranial pulse stimulation; tVNS, Transcu-
taneous vagal nerve stimulation
NOTE: Thirty-three device trials currently ongoing (“recruiting,” “active, not recruiting,” and “not yet recruiting”) as of February 12, 2019 according to
clinicaltrials.gov.
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based ATN framework for the diagnosis and characterization
of AD [7]. This framework will assist in trials with both ac-
curate diagnosis of AD and biological staging of AD rele-
vant to matching the trial population to the MOA of the
agent being assessed [8]. Of the disease-modifying trials
currently in the AD pipeline, 52 use amyloid imaging and/
or CSF to support the diagnosis, 20 have amyloid imaging
as an outcome, ten have tau imaging as an outcome of the
intervention. In addition to the specific biomarkers included
in the ATN framework, evidence is accruing that the plasma
amyloid 40/42 ratio corresponds to the presence of cerebral
amyloidosis [34] and that plasma neurofilament light is
indicative of neurodegeneration [35]. These increasingly
available biomarkers will facilitate screening for clinical tri-
als and may have a role in course prediction and assessing
treatment outcome.
Design innovations are evident in recent trials of AD ther-
apeutics. Futility analyses were used to terminate develop-
ment programs for pioglitazone, verubecestat [27],
crenezumab, ITI-007, LY3314814 (lanabecestat), and adu-
canumab. Futility analyses are conducted when the trial is
incomplete but when sufficient data are available to predict
if continuing the trial could meet prespecified criteria [36].
The Alzheimer’s Disease Composite Score (ADCOMS)
[37] has been introduced as a cognitive outcome in several
development programs including BAN2401, elenbecestat,
and xanamem. The ADCOMS is an analytic approach
whose score is based on combining scores on items
derived from the Alzheimer’s Disease Assessment Scale–
cognitive subscale, clinical dementia rating, and Mini-
Mental State Examination [38] after these tools are admin-
istered in the standard way. ADCOMS constituents were
derived from trials of patients with MCI that showed the
most change over a one-year period to develop a score
that is most likely to show a drug-placebo difference in tri-
als of patients with early-stage disease and very limited
cognitive deficits.
Bayesian adaptive designs are being implemented in
AD trials. These have been used broadly in non-AD trials
including development of cancer and diabetes therapies
[39,40]. Adaptive trials are being used in the BAN2401
trial, Dominantly Inherited Alzheimer Network–
Treatment Unit [41], European Prevention of Alzheimer
Disease initiative [42], and the Intranasal Oxytocin for
Fronto-temporal Dementia (FOXY) trial of intranasal
oxytocin for frontotemporal dementia [43]. The trial of
ABT-089 pioneered the use of an adaptive design in AD
[44]. Bayesian designs use data derived from the ongoing
trial to inform dose allocation, trial duration, sample size,
or response to adverse events; decisions are prespecified
before trial initiation. Dose-adaptive designs are
participant-centric in that they allow study subjects to be
assigned to the doses most likely to succeed or least likely
to produce adverse events.
It has been argued that there is no “pipeline” of drug
development because agents often do not proceed systemat-
ically from phase 1 to phase 3 and irregularities are common
[45]. We use the word “pipeline” to categorize agents in
early, middle, and late-stage trials. In AD drug development,
agents tend to proceed from phase 1 single and multiple
ascending dose studies to phase 2 proof-of-concept (POC)
studies, and then to phase 3 registration-type trials. Testing
for POC in phase 2 depends on dose ranges and safety estab-
lished in phase 1 and provides the foundation for phase 3.
Repurposed agents may have irregular pathways going
from approved status for one indication to phase 1 or phase
2 to define dose and POC before testing in phase 3 for the AD
indication [46,47]. The concept of “pipeline” applies as an
imprecise but generally accurate overview of drug
development for AD.
There are more agents in the AD pipeline in 2019 than
was observed in the 2018 pipeline. There are 28 agents in
phase 3 (compared with 26 in 2018), 74 agents in phase 2
(compared with 63 in 2018), and 30 in phase 1 (compared
with 23 in 2018).
The lack of success in AD drug development has given
rise to nihilism with regard to the ability of the field to
develop agents that meaningfully modify the progression
of AD. Suggestions to abandon the amyloid hypothesis,
focus exclusively to combination therapies, place more
emphasis on lifestyle interventions to prevent AD or reassess
our assumptions and build new models to drive drug devel-
opment are all voiced, and each of these perspectives have
merit. Reviews of the pipeline show that lessons are learned
from all trials; even negative and futile outcomes are highly
informative and provide guidance for future trials. The over-
view of trials document a shift toward more diversification of
targets between phase 3 and phase 2, the entry of combina-
tion therapies into the pipeline, and the use of biomarkers to
allow early assessments of the impact of candidate interven-
tions on disease biology.
Several agents have shown no drug-placebo difference,
and the development programs have been discontinued. A
few programs successfully demonstrated drug-placebo dif-
ferences in phase 2 and are advancing. Progress depends
on innovation and learning from exploration of new tar-
gets, assessment of new candidates, and implementation
of new trial features. As in other chronic disease such as
cancer, human immunodeficiency virus (HIV), and cardio-
vascular disease, a learning phase preceded periods whose
sequential incremental successes led to meaningful treat-
ments.
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RESEARCH IN CONTEXT
1. Systematic review: There is a high rate of failure of
drug development for Alzheimer’s disease. New
treatments are urgently needed, and review of the
drug development pipeline can improve our under-
standing of how best to advance new therapies. We
reviewed all drugs currently in clinical trials for Alz-
heimer’s disease listed in the federal government
database clinicaltrials.gov.
2. Interpretation: We showed that there are 132 agents
in clinical trials for the treatment for Alzheimer’s
disease. Ninety-six of these drugs are disease-
modifying agents intended to change the underly-
ing biology of Alzheimer’s disease. Nineteen of the
drugs are intended to be cognitive enhancing
agents, and 14 are being developed for the treat-
ment of neuropsychiatric and behavioral symp-
toms. We provide an overview of drugs currently in
clinical trials for Alzheimer’s disease.
3. Future directions: Progress is being made in terms of
defining new targets for the treatment of Alzheimer’s
disease, developing new agents, introducing innova-
tive clinical trial designs, incorporating a broader
range of populations in clinical trials, and developing
new biomarkers that provide insight into the impact
of emerging therapies. Improvements in drug devel-
opment success rates are anticipated.
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